GLP-1 news roundup: Retatrutide Phase 3 results, an oral approval and new eye warnings

What the source reports

Eli Lilly reported positive topline results from two 80-week Phase 3 trials of Retatrutide on 23 July 2026. Retatrutide is an investigational once-weekly molecule that activates GIP, GLP-1 and glucagon receptors; it is not currently approved for sale or human use.

In TRIUMPH-2, which enrolled 1,152 adults with type 2 diabetes and obesity or overweight, the highest studied dose was associated with an average body-weight change of 20.8% (49.6 lb or 22.5 kg) at 80 weeks, compared with 4.0% (9.3 lb or 4.2 kg) for placebo, using Lilly's efficacy estimand.

In TRIUMPH-3, which enrolled 1,949 adults with severe obesity and established cardiovascular disease, the highest studied dose was associated with an average body-weight change of 22.6% (55.8 lb or 25.3 kg), compared with 3.2% (7.7 lb or 3.5 kg) for placebo at 80 weeks.

Lilly also reported average reductions at the highest TRIUMPH-3 dose of 37.0% in triglycerides, 16.5% in non-HDL cholesterol, 9.3 mmHg in systolic blood pressure and 51.2% in high-sensitivity C-reactive protein. The cardiovascular-event confidence intervals crossed 1, so these data do not establish a cardiovascular-event benefit.

The company says it plans to submit Retatrutide for US approval in the first quarter of 2027. Detailed TRIUMPH-2 and TRIUMPH-3 results have not yet been presented at a medical meeting or published in a peer-reviewed journal.

An oral GLP-1 medicine gains US approval

The US Food and Drug Administration approved Foundayo (orforglipron) on 1 April 2026 for long-term weight reduction in adults with obesity, or adults with overweight and at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity.

Orforglipron is a once-daily, small-molecule, non-peptide GLP-1 receptor agonist tablet. The FDA says two 72-week randomised, double-blind, placebo-controlled trials supported the approval. Its label includes side effects, precautions and a boxed warning, so the approval does not mean the medicine is appropriate for every individual.

Australia updates warnings about a rare eye condition

Australia's Therapeutic Goods Administration announced updated product information across the GLP-1 receptor agonist class on 23 July 2026 concerning non-arteritic anterior ischaemic optic neuropathy, known as NAION, a rare but serious condition that can cause permanent visual impairment.

The regulator said the available evidence was conflicting. Its advisory committee considered that the signal may be supported for semaglutide, but not for dulaglutide or tirzepatide. Product information now records reported events across the class, and the TGA advises urgent medical assessment following sudden loss of vision, including partial loss.

An observational alcohol-hospitalisation signal

A Swedish register-based observational study published online by The Lancet Psychiatry included 167,026 people with type 2 diabetes. During periods of GLP-1 receptor agonist exposure, alcohol-use-disorder-related hospitalisations occurred at a lower rate than during unexposed periods in the same individuals, with a rate ratio of 0.55 and a 95% confidence interval from 0.43 to 0.70.

This was an observational association, not a randomised treatment trial. It cannot establish that GLP-1 medicines caused the lower hospitalisation rate, and it does not support using these medicines as an approved treatment for alcohol use disorder.

Study or regulatory context

These developments sit at different evidence stages. Retatrutide has new company-reported Phase 3 topline data but remains investigational. Orforglipron has completed US regulatory review for a defined indication. The Australian update concerns post-market safety monitoring, while the alcohol study is observational research that can identify associations but not prove cause and effect.

The distinctions matter: a trial result is not an approval, an approval is not a recommendation for every person, a safety signal is not proof that every medicine has the same risk, and an observational association is not evidence of a new approved use.

What remains uncertain

Retatrutide's complete Phase 3 datasets, peer-reviewed analyses and regulatory decisions are still pending. Lilly's planned submission timing is not an approval date, and regulators may request additional information.

The absolute size and medicine-specific pattern of any NAION risk remain under study. The TGA describes NAION as rare and notes that the evidence differs between individual medicines.

Randomised clinical trials would be needed to determine whether GLP-1 receptor agonists have a treatment role in alcohol use disorder. The Swedish study alone cannot answer that question.